[1]
Johnstone, T.C.; Suntharalingam, K.; Lippard, S.J. The next generation of platinum drugs: targeted pt(ii) agents, nanoparticle delivery, and pt(iv) prodrugs. Chem. Rev., 2016, 116(5), 3436-3486.
[http://dx.doi.org/10.1021/acs.chemrev.5b00597]
[http://dx.doi.org/10.1021/acs.chemrev.5b00597]
[2]
Marzo, T.; Ferraro, G.; Merlino, A.; Messori, L. Protein metalation by inorganic anticancer drugs.In:Encyclopedia of Inorganic and Bioinorganic Chemistry; Wiley: Hoboken, 2020.
[http://dx.doi.org/10.1002/9781119951438.eibc2747]
[http://dx.doi.org/10.1002/9781119951438.eibc2747]
[3]
Miodragović, D.; Merlino, A.; Swindell, E.P.; Bogachkov, A.; Ahn, R.W.; Abuhadba, S.; Ferraro, G.; Marzo, T.; Mazar, A.P.; Messori, L.; O’Halloran, T.V. Arsenoplatin-1 is a dual pharmacophore anticancer agent. J. Am. Chem. Soc., 2019, 141(16)
[http://dx.doi.org/10.1021/jacs.8b13681]
[http://dx.doi.org/10.1021/jacs.8b13681]
[4]
Merlino, A.; Marzo, T.; Messori, L. Protein metalation by anticancer metallodrugs: a joint esi ms and xrd investigative strategy. Chem.- A Eur. J, 2017, 23(29)
[http://dx.doi.org/10.1002/chem.201605801]
[http://dx.doi.org/10.1002/chem.201605801]
[5]
La Mendola, D.; Giacomelli, C.; Rizzarelli, E. Intracellular bioinorganic chemistry and cross talk among different -omics. Curr. Top. Med. Chem., 2016, 16(27), 3103-3130.
[http://dx.doi.org/10.2174/1568026616666160715164212]
[http://dx.doi.org/10.2174/1568026616666160715164212]
[6]
Kilari, D.; Guancial, E.; Kim, E.S. Role of copper transporters in platinum resistance. World J. Clin. Oncol., 2016, 7(1), 106.
[http://dx.doi.org/10.5306/wjco.v7.i1.106]
[http://dx.doi.org/10.5306/wjco.v7.i1.106]
[7]
Naletova, I.; Cucci, L.M.; D’Angeli, F.; Anfuso, C.D.; Magrì, A.; La Mendola, D.; Lupo, G.; Satriano, C. A tunable nanoplatform of nanogold functionalised with angiogenin peptides for anti-angiogenic therapy of brain tumours. Cancers (Basel), 2019, 11(9), 1322.
[http://dx.doi.org/10.3390/cancers11091322]
[http://dx.doi.org/10.3390/cancers11091322]